Form 4: ARTIVION Director Elizabeth Hoff Receives Significant Equity Grant

ARTIVION, Inc. Director Elizabeth A. Hoff was granted 6,325 shares of common stock as part of an equity incentive plan, increasing her total beneficial ownership to 31,389 shares.

Summary

• Elizabeth A. Hoff, a Director of ARTIVION, INC. (AORT), acquired 6,325 shares of common stock.
• The transaction occurred on May 22, 2025, and was an acquisition (A) of securities.
• The shares were granted at a price of $0, indicating a Restricted Stock Award (RSA).
• Following this transaction, Ms. Hoff's total beneficial ownership of ARTIVION common stock increased to 31,389 shares.
• The RSA grant is scheduled to vest on May 22, 2026, in accordance with the terms of the company's Equity and Cash Incentive Plan.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as the equity grant aligns the director's interests with shareholders, which is generally viewed favorably. However, it's a routine compensation event and not indicative of significant operational or financial breakthroughs.

Positives

• The grant of restricted stock to a director aligns their long-term interests with those of the shareholders, encouraging a focus on sustained company performance.
• Equity compensation is a standard practice that helps attract and retain qualified board members.

Future Outlook

The future outlook indicates that the granted shares will vest on May 22, 2026, contingent on the terms of the Equity and Cash Incentive Plan, solidifying the director's long-term stake in the company.

Management Comments

• Elizabeth A. Hoff, a Director of ARTIVION, INC., received 6,325 shares of common stock as a Restricted Stock Award (RSA) on May 22, 2025, which will vest on May 22, 2026, under the company's Equity and Cash Incentive Plan.

Industry Context

Equity grants, such as Restricted Stock Awards, are a common form of compensation for directors and executives in publicly traded companies across various industries, including the medical device and healthcare sector where ARTIVION operates. This practice is designed to align the interests of company leadership with those of shareholders by tying a portion of their compensation to the company's stock performance.

Comparison to Industry Standards

• The grant of restricted stock to a director is a standard component of compensation packages for board members in public companies, consistent with corporate governance best practices aimed at aligning director incentives with long-term shareholder value.
• While specific comparable companies or projects are not detailed in this Form 4, such equity grants are widely observed across the medical technology industry, including companies like Medtronic, Edwards Lifesciences, and Boston Scientific, which frequently utilize similar incentive plans for their leadership.

Corporate Governance

Related Party Transactions

• The transaction involves the issuance of common stock by ARTIVION, INC. to Elizabeth A. Hoff, a Director of the company, which constitutes a related party transaction as per SEC regulations.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with shareholder value, potentially leading to more shareholder-centric decision-making.
• Employees: While not directly impacted, such compensation practices can set a precedent for executive and director incentives within the company.

Next Steps

• The 6,325 Restricted Stock Award shares are scheduled to vest on May 22, 2026, at which point they will become fully owned by Elizabeth A. Hoff.

Key Dates

Keywords

ARTIVION, AORT, Form 4, SEC filing, insider transaction, equity grant, restricted stock award, director compensation, beneficial ownership, corporate governance